• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    5/2/24 12:31:17 PM ET
    $ARAY
    $BCAB
    $BRKR
    $EBS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARAY alert in real time by email

    Gainers

    • Emergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday.
    • Nuwellis (NASDAQ:NUWE) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million.
    • Sensei Biotherapeutics (NASDAQ:SNSE) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million.
    • Syra Health (NASDAQ:SYRA) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million.
    • Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million.
    • Titan Pharma (NASDAQ:TTNP) shares moved upwards by 25.37% to $8.4. The market value of their outstanding shares is at $7.6 million.

    Losers

    • Accuray (NASDAQ:ARAY) shares fell 27.6% to $1.57 during Thursday's regular session. The market value of their outstanding shares is at $155.6 million. As per the press release, Q3 earnings came out yesterday.
    • Metagenomi (NASDAQ:MGX) shares fell 17.62% to $5.8. The market value of their outstanding shares is at $217.3 million.
    • Elevation Oncology (NASDAQ:ELEV) stock fell 11.26% to $3.55. The company's market cap stands at $172.7 million. The company's, Q1 earnings came out today.
    • Bruker (NASDAQ:BRKR) stock fell 11.13% to $70.24. The company's market cap stands at $10.2 billion. As per the news, the Q1 earnings report came out today.
    • Ocean Biomedical (NASDAQ:OCEA) stock fell 10.97% to $1.34. The company's market cap stands at $46.4 million.
    • BioAtla (NASDAQ:BCAB) stock declined by 10.84% to $3.0. The market value of their outstanding shares is at $144.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY
    $BCAB
    $BRKR
    $EBS

    CompanyDatePrice TargetRatingAnalyst
    BioAtla Inc.
    $BCAB
    1/13/2026$4.00Buy
    Rodman & Renshaw
    Bruker Corporation
    $BRKR
    12/10/2025$60.00Peer Perform → Outperform
    Wolfe Research
    Bruker Corporation
    $BRKR
    12/9/2025$40.00Sell
    Goldman
    Bruker Corporation
    $BRKR
    11/20/2025$60.00Buy
    Rothschild & Co Redburn
    BioAtla Inc.
    $BCAB
    8/13/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Sensei Biotherapeutics Inc.
    $SNSE
    6/2/2025$5.00Buy
    H.C. Wainwright
    Bruker Corporation
    $BRKR
    5/22/2025$40.00Buy → Neutral
    Citigroup
    Elevation Oncology Inc.
    $ELEV
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $ARAY
    $BCAB
    $BRKR
    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioAtla with a new price target

    Rodman & Renshaw initiated coverage of BioAtla with a rating of Buy and set a new price target of $4.00

    1/13/26 3:22:40 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bruker upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00

    12/10/25 9:02:11 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Bruker with a new price target

    Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00

    12/9/25 8:43:14 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ARAY
    $BCAB
    $BRKR
    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    CEO La Neve Stephen R. bought $19,410 worth of shares (20,000 units at $0.97) (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    11/19/25 5:18:33 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    $BCAB
    $BRKR
    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C covered exercise/tax liability with 37,055 shares, decreasing direct ownership by 11% to 305,445 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    3/5/26 9:40:29 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fowler John D Jr was granted 5,006 shares (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    3/5/26 9:38:11 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Fowler John D Jr claimed no ownership of stock in the company (SEC Form 3)

    3 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    3/5/26 9:37:49 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAY
    $BCAB
    $BRKR
    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

    Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application ("IND") in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on it

    3/5/26 4:05:00 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results

    CARMEL, Ind., March 5, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA), ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today that it will report financial results for its fourth quarter and fiscal year ended December 31, 2025, on Thursday, March 12, 2026. The results will be shared in a press release before the market opens.About Syra HealthSyra Health is an integrated healthcare solutions company serving government and commercial healthca

    3/5/26 7:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    $ARAY
    $BCAB
    $BRKR
    $EBS
    SEC Filings

    View All

    SEC Form S-8 filed by Metagenomi Therapeutics Inc.

    S-8 - Metagenomi Therapeutics, Inc. (0001785279) (Filer)

    3/5/26 4:20:34 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Metagenomi Therapeutics Inc.

    10-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)

    3/5/26 4:14:23 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Metagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)

    3/5/26 4:09:43 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARAY
    $BCAB
    $BRKR
    $EBS
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

    GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i

    3/3/26 8:00:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARAY
    $BCAB
    $BRKR
    $EBS
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

    2/26/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

    Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ET Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The

    2/18/26 8:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAY
    $BCAB
    $BRKR
    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:05:59 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 6:45:37 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care